Clinical trials
Locally Advanced Pancreatic Adenocarcinoma clinical trials
Below are recruiting locally advanced pancreatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 189 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07478523RecruitingPhase 2
FAPI-PET scan for initial screening of pancreatic and bile duct cancers
This trial tests a new imaging method called FAPI-PET to see if it can better detect pancreatic and bile duct cancers at an early stage. It may help doctors decide on the best treatment plan for you.
PessacAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT05776524RecruitingPhase 2
Radiofrequency heat treatment for pancreas cancer spread to other organs
This Phase 2 trial tests whether a device that delivers carefully timed “radiofrequency heat” through the body can slow or control metastatic (spread) pancreatic cancer. You may qualify if you have newly diagnosed metastatic pancreatic cancer and can meet safety and blood-test requirements.
Winston-Salem, North CarolinaAges 18 years+ - NCT05205850RecruitingPhase 1/Phase 2
RC118 for solid cancers with Claudin 18.2 on tumor cells
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06898385RecruitingPhase 1
IX001 TCR-T Cells for Advanced Pancreatic Cancer with KRAS G12V
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06598007RecruitingPhase 1/Phase 2
Studying CT3001 for advanced solid tumors
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
Houston, TexasAges 18 years+ - NCT02869802Recruiting
Study types of pancreatic cancer using tumor gene testing
This trial studies metastatic pancreatic cancer by taking a small tissue sample and analyzing its genes. It may help doctors better understand which cancer subtypes patients have, which can guide future treatment choices.
Calgary, AlbertaAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06412510RecruitingPhase 1/Phase 2
Exercise before chemo for several cancers
This trial tests a prehab program for older adults with certain cancers before they begin chemotherapy. The program may help you feel stronger and handle treatment better.
Cleveland, OhioAges 65 years+ - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT05857332RecruitingPhase 1
Testing a new drug for CLDN18.2-positive solid tumors
This Phase 1 study tests SG1906, a new investigational drug, in people with certain advanced solid tumors that test positive for CLDN18.2. The goal is to see whether the drug is safe and to learn how well it may work in shrinking tumors or controlling the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05776342Recruiting
Markers study for treatment response in pancreatic cancer
This study looks at tumor “markers” (tests on cancer tissue or related information) to understand how you may respond to first-line treatment for pancreatic cancer. Your results may help doctors better predict which treatments work best for different people.
BesançonAges 18 years+ - NCT07235930RecruitingPhase 3
New drug combo for advanced pancreatic cancer
This trial tests a combination of chemotherapy plus two targeted drugs (serplulimab and bevacizumab) against chemotherapy alone for pancreatic cancer that cannot be removed by surgery or has spread. This approach may help shrink or stabilize the tumor longer.
Hangzhou, ZhejiangAges 18–75 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT06219941RecruitingPhase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
Orange, CaliforniaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Santa Rosa, CaliforniaAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Phoenix, ArizonaAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT05947825Enrolling by invitationPhase 2
Sitagliptin plus chemo for advanced pancreatic cancer
This trial tests adding sitagliptin (a diabetes drug) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to see if the combination works better than chemo alone.
TianjingAges 18 years+ - NCT06467565RecruitingPhase 2
NALIRIFOX chemotherapy for locally advanced pancreatic cancer
This trial tests a combination of chemotherapy drugs (NALIRIFOX) as a first treatment for people with locally advanced pancreatic cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Nanjing, JiangsuAges 18–70
Hear when a new Locally Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced pancreatic adenocarcinoma?
- Yes. Clin2 currently lists 189 recruiting locally advanced pancreatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced pancreatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Cancer
- Locally Advanced Gastric Adenocarcinoma
- Locally Advanced Gastroesophageal Junction Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.